Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
The initiative will encourage and motivate emerging biotech startups, innovators and entrepreneurs
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
With the addition of Karsanbhai, the Merck board will consist of 13 members
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
Subscribe To Our Newsletter & Stay Updated
